Explore Poster titles that will be presented at the 2022 IKCS: North America meeting. Posters will be available in-person and online. Posters will be hung up by 12:00 PM on Friday, November 4 and will remain hanging until the meeting ends on the afternoon of Saturday, November 5.
Poster Walks are small group tours of the posters where participants can ask questions to presenters, discuss research with other attendees, and glean insights from Faculty.
Poster Walks will take place in-person and virtually on Friday, November 4 from 5:30 PM- 6:15 PM CDT.
Regular Abstracts: Poster Boards A1- E1; E3- E7
Case Reports: Poster Board E8
Trials in Progress Abstracts: Poster Boards F1- F7
Basic Science: Poster Boards A1- A2
Imaging: Poster Board A3
Patient-reported Outcomes: Poster Board A5
Post-treatment Surveillance: Poster Boards A6- A7
Quality of Care and Quality Improvement: Poster Boards A8- B3
Real-World Evidence: Poster Boards B4- C1
Survivorship: Poster Boards C2- C3
Therapeutics (Local- Primary and Metastases): Poster Boards C4- C5
Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.): Poster Boards C6- E1; F1- F7
Treatment Toxicities and Symptom Management: Poster Boards E2- E3
Tumor Biology, Biomarkers, and Pathology: Poster Boards E4- E7
Other: Poster Boards A4, E8
Abstract 9: DNA methylation-based tumor microenvironment deconvolution in clear cell renal cell carcinoma reveals significant survival association with specific cell types
Presenter: Ze Zhang
Abstract 10: Epigenetic Dysregulation Activates the Oncogenic Dicarboxylic Amino Acid Transporter SLC1A1 in ccRCC
Presenter: Abhishek Chakraborty
Abstract 11: Differentiation Clear Cell Renal Cell Carcinoma from Other Common Malignant and Benign Renal Masses on Multiphasic MRI: A Likert Based Multireader Analysis
Presenter: Chuthaporn Surawech (Alternate Presenter: Steve Raman)
Abstract 12: Outcomes of active surveillance for young and healthy patients with small renal masses
Presenter: Muammer Altok
Abstract 13: The Role of Exercise on the Physical and Mental Health of Kidney Cancer Patients and Survivors
Presenter: Daniel Roberson
Abstract 14: Risk factors for end stage renal disease after treatment of renal cell carcinoma
Presenter: Sven Lundstam
Abstract 15: Survival Outcomes Following Adoption of Risk-Adjusted AUA Surveillance Guidelines After Partial Nephrectomy
Presenter: Wesley Yip
Abstract 16: Artificial intelligence modelling to predict the risk of cardiotoxicity among renal cell carcinoma patients treated with vascular endothelial growth factor receptors tyrosine kinase inhibitors.
Presenter: Hesham Yasin
Abstract 17: Kidney cancer clinical trials: a decision aid for patients and clinicians
Presenter: Rachel Giles (Alternate Presenter: Eric Jonasch)
Abstract 18: Non-Index vs Index Readmissions Following Radical Nephrectomy: Causes, Costs, and Outcomes
Presenter: Shiva Balasubramanian
Abstract 19: Non-Index vs Index Readmissions Following Partial Nephrectomy: Causes, Costs, and Outcomes
Presenter: Shiva Balasubramanian
Abstract 20: Real-world Clinical Outcomes of Patients (pts) with Metastatic Renal Cell Carcinoma (mRCC) Receiving Pembrolizumab + Axitinib (P+A) vs Ipilimumab + Nivolumab (I+N)
Presenter: Neil J. Shah
Abstract 21: Short-Term Outcomes of Active Surveillance for Small Renal Masses in Patients With End-Stage Renal Disease and Immunosuppression
Presenter: Zoe Gan
Abstract 22: Healthcare resource utilization (HCRU) and costs in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line (LOT1) pembrolizumab + axitinib (P+A) or ipilimumab + nivolumab (I+N)
Presenter: Neil J. Shah
Abstract 23: Real-world Assessment of Changing Treatment Patterns and sequence for patients with Metastatic Renal Cell Carcinoma (mRCC) in the first-line (1L) setting
Presenter: Neil J. Shah
Abstract 24: Depth of response associated with first-line immunotherapy-based combinations in metastatic clear cell renal cell carcinoma.
Presenter: Kelly Fitzgerald
Abstract 25: Clinical manifestations of Birt-Hogg-Dube Syndrome in a large clinical cohort
Presenter: Raju Chelluri
Withdrawn
Withdrawn
Abstract 28: Treatment decisions among patients newly diagnosed with clinical T1 renal masses
Presenter: Kathryn Gessner
Abstract 29: Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint therapy (ICT)
Presenter: Andrew Hahn
Abstract 30: Treatment-free survival (TFS) in patients with advanced renal cell carcinoma (aRCC) treated with nivolumab and ipilimumab (NIVO/IPI) versus sunitinib (SUN): 60-month update of Checkmate 214
Presenter: Charlene Mantia
Abstract 31: Updated efficacy of lenvatinib + pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
Presenter: Camillo G. Porta (Alternate Presenter: Bradley McGregor)
Abstract 32: Efficacy and safety of nivolumab plus ipilimumab versus sunitinib for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up
Presenter: Nazir Tannir
Abstract 33: Long-term PFS from TIVO-3: Tivozanib (TIVO) vs sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC
Presenter: Michael Atkins
Abstract 34: Characterization of Patients Undergoing Consolidative Nephrectomy after Immunotherapy
Presenter: Stephen Reese
Abstract 35: Activity of tivozanib in non-clear cell renal cell carcinoma (nccRCC): Subgroup analysis from a phase 2 randomized discontinuation trial
Presenter: Pedro Barata
Abstract 36: Impact of subsequent therapies in patients with advanced renal cell carcinoma (aRCC) receiving lenvatinib plus pembrolizumab or sunitinib in the CLEAR study
Presenter: Martin H. Voss
Abstract 37: A randomized phase 2 study with a cell-based immune primer plus sunitinib versus sunitinib aone in metastatic Renal Cell Carcinoma.
Presenter: Börje Ljungberg
Abstract 38: Association between depth of response (DepOR) and clinical outcomes: exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER
Presenter: Andrea Apolo (Alternate Presenter: Bernard Escudier)
Abstract 39: Maturation of overall survival (OS) in TIVO-3 with long-term follow-up
Presenter: Brian Rini
Abstract 40: Phase 1 trial of combination therapy with avelumab and cabozantinib in patients with newly diagnosed metastatic clear cell renal cell carcinoma
Presenter: Haoran Li
Abstract 41: Efficacy of nivolumab plus ipilimumab in T1aN0M0 renal cell carcinoma patients ineligible for surgery and ablation
Presenter: Ilya Tsimafeyeu
Withdrawn
Abstract 43: Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma
Presenter: James Schuster
Abstract 44: NF2-Mutant Renal Cell Carcinoma: A Comprehensive Characterization of a Lethal Unclassified Renal Cell Carcinoma
Presenter: Stephen Reese
Abstract 45: Metagenomic analysis of the gut microbiome in metastatic renal cell carcinoma patients with sarcopenia
Presenter: Neal Chawla
Abstract 46: Prospective evaluation of mutation concordance between standard-of-care renal mass biopsy and nephrectomy specimens in small renal masses
Presenter: Kathryn Gessner
Abstract 47: Epigenetic, transcriptional, and compositional shifts in clear cell renal cell carcinomas
Presenter: Lucas Salas
Abstract 48: A Case of Metastatic Renal Cell Carcinoma to The Maxillary Sinus Initially Presenting as Recurrent Epistaxis
Presenter: Justin Mehr
Abstract 49: A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL / Alliance A031801)
Presenter: Rana McKay
Abstract 50: TiNivo-2: A Phase 3 Study to Compare Tivozanib+Nivolumab to Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Who Have Progressed Following ≤2 Lines of Therapy including an Immune Checkpoint Inhibitor (ICI)
Presenter: Toni Choueri
Abstract 51: A phase II study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma (mRCC) that progressed on a PD-1/PD-L1 checkpoint inhibitor (LenCabo)
Presenter: Andrew Hahn
Abstract 52: LITESPARK-011: a randomized, phase 3 study of belzutifan plus lenvatinib versus cabozantinib after anti–PD-1/PD-L1 therapy in patients with advanced renal cell carcinoma
Presenter: Daniel YC Heng
Abstract 53: Phase 2 trial for sequential treatment after cabozantinib progression in metastatic renal cell carcinoma (Seq-Cabo)
Presenter: Qian Qin
Abstract 54: APART – A Phase 2 trial of Axitinib, Palbociclib and Avelumab as advanced Clear Cell Renal Cell Carcinoma (ccRCC) Therapy
Presenter: Stephanie Berg
Abstract 55: A pilot study of the immunomodulatory agent acarbose in combination with standard therapy in metastatic renal cell carcinoma (RCC)
Presenter: Arnab Basu